Treating tumors with ADU-S100, an agonist of the STING DNA-sensing pathway47, increased the presence of TILs presumably targeting uncharacterized tumor antigens (Fig. 3D) but had little therapeutic effect. The gene discussed is STING1; the disease is neoplasm.